The first subject, with blood LDL-cholesterol (“bad cholesterol”) levels greater than 130 mg/dL, has undergone the initial medical examination for the HEART protocol on the active substance TOTUM-070. The HEART study will include 120 people with elevated blood LDL-cholesterol, a risk factor for cardiovascular disease and the primary endpoint of […]
Coronary/Structural Heart
Study Confirms Elucid’s AI Software Accurately Estimates Lesion-Specific Ischemia Compared to Standard of Care
BOSTON–(BUSINESS WIRE)–Elucid, a medical technology company developing AI software to enable cardiovascular disease detection, announced today the publication of new clinical data in the International Journal of Cardiology. The study, entitled “Coronary plaque assessment of Vasodilative capacity by CT angiography effectively estimates fractional flow reserve” demonstrates that Fractional Flow Reserve (FFR) […]
Medtronic Announces Voluntary Recall of Unused Valiant Navion™ Thoracic Stent Graft System
DUBLIN, Feb. 17, 2021 /PRNewswire/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, has voluntarily issued a global recall of unused Medtronic Valiant Navion™ thoracic stent graft system and informed physicians to immediately cease use of the device until further notice. In accordance with its commitment to patient safety – […]
Silence Therapeutics Initiates Dosing in Phase 1 Clinical Trial of SLN360 for Cardiovascular Disease Due to High Lipoprotein(a)
Silence Therapeutics Initiates Dosing in Phase 1 Clinical Trial of SLN360 for Cardiovascular Disease Due to High Lipoprotein(a) 17 February 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics […]
Shockwave Intravascular Lithotripsy FDA Approved to Treat Advanced Heart Disease
Transformative Technology Now Available for Calcified Coronary Plaque SANTA CLARA, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company’s sonic pressure wave therapy received Pre-Market Approval for […]
Dr. Sanjay Rajagopalan Recognized With American College of Cardiology Top Honor
Rajagopalan to be presented with the Distinguished Scientist Award – Translational Domain during ACC’s 70th Annual Scientific Session CLEVELAND — Sanjay Rajagopalan, MD, FACC, has been awarded the 2021 Distinguished Scientist Award – Translational Domain by the American College of Cardiology (ACC) for his contributions to the cardiovascular profession. Dr. […]
Windtree Announces Issuance of New U.S. Patent Covering Technology on Its Redesigned AEROSURF® Device
New patent covers updated aerosol delivery system and design until 2039 WARRINGTON, Pa., Feb. 16, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that the United States Patent and Trademark Office (USPTO) […]
Heart Valve Disease Awareness Day Campaign Celebrates Fifth Anniversary with Focus on Health Disparities
Advocates Continue to Drive Forward Heart Valve Disease Awareness, While Highlighting the Inequities in Risk Factors, Diagnosis, and Treatment Faced by Black Americans WASHINGTON, Feb. 16, 2021 /PRNewswire/ — On Monday, February 22, more than 90 national organizations and thousands of patient advocates will recognize the fifth anniversary of the annual HVD Awareness Day (“Valve Disease […]
Orsini Specialty Pharmacy Selected To Be The Exclusive Specialty Pharmacy Partner For Evkeeza™ (evinacumab-dgnb)
ELK GROVE VILLAGE, Ill., Feb. 16, 2021 /PRNewswire/ — Orsini Specialty Pharmacy, a leader in rare diseases and gene therapies, announced today that it has been selected by Regeneron Pharmaceuticals, Inc. as the exclusive specialty pharmacy partner for EvkeezaTM (evinacumab-dgnb). Evkeeza is approved by the U.S. Food and Drug Administration (FDA) as an adjunct […]
WeHealth™ Digital Medicine and BioSerenity Initiate a New Phase to Accelerate Cardioskin™ Commercialization
BioSerenity acquires Cardioskin™ global distribution rights PARIS and ATLANTA, Feb. 16, 2021 /PRNewswire/ — WeHealth™ Digital Medicine (e-health division of the Servier Group) and BioSerenity announced today that BioSerenity gains global distribution rights for Cardioskin™, the first WeHealth™ digital Solution co-developped with a start-up, to accelerate the commercialization of Cardioskin™. After successfully collaborating to develop the Cardioskin™, the […]



